000403.SZ
派林生物
SZSE · Healthcare · C 制造业 · CN
CNY 10.26
−3.48%Year over year
Reported trailing growth
- Revenue
- +0.3%
- EBITDA
- —
- EBIT
- -46.6%
- EPS
- -47.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -62.6%
- EBITDA
- -21.6%
- EPS
- +5.4%
Three-year CAGR
- Revenue
- +3.1%
- EBITDA
- -5.0%
- EBIT
- -7.4%
- Net income
- -10.6%
- EPS
- -18.2%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026